The Opportunity at a Glance

Sensiks has developed a comprehensive sensory computing platform that delivers clinically-validated mental health outcomes through synchronized multisensory stimulation and real-time biofeedback. With proven technology, blue-chip customers, and positive cash flow, we're raising:

€8M at a €27M pre-money valuation to scale commercial operations and advance regulatory pathways

Addressing a €600 Billion Crisis

Europe faces a mental health emergency affecting nearly half of all adults, costing over €600 billion annually in healthcare expenses and lost productivity. Current solutions—pharmaceuticals with high relapse rates, therapy with six-month wait times, digital apps with poor engagement—fail to directly recalibrate the underlying physiological dysregulation driving mental health conditions.

The market demands non-invasive, precision-engineered interventions capable of rapidly shifting autonomic nervous system states while delivering measurable, lasting outcomes.

The Sensiks Solution: Sensory Reality™

Our full-stack platform integrates proprietary hardware pods, intelligent orchestration software, and an AI-powered personalization engine (SENSAI™) to deliver synchronized stimulation across six sensory channels: visual, auditory, olfactory, haptic, thermal, and airflow.

Clinically meaningful improvements achieved in 10–30 minute sessions:

• 20–35% gains in heart rate variability (stress resilience)
• 30–60% reductions in anxiety scores
• 30–40 point drops in PTSD symptoms

Unlike competing solutions, our platform creates a bio-adaptive enhancement layer that amplifies existing mental health tools rather than replacing them—making digital therapeutics more effective, virtual reality more immersive, and traditional therapy more accessible.

Why It Works: The Neuroscience Foundation

Our efficacy is grounded in five established neuroscience principles:

Multisensory Integration (MSI): The brain processes information significantly faster when multiple senses are engaged simultaneously. Cross-modal synergies create stronger neural activation, leading to deeper emotional engagement and enhanced memory formation.

PNEI (Psycho-Neuro-Endocrine-Immunology) Pathways: Sensory stimulation directly modulates the autonomic nervous system and activates the HPA axis for stress response regulation. Effects extend to immune function through cytokine modulation and natural killer cell activation.

State Priming & Conditioning: Repeated multisensory experiences create conditioned neural responses. Through pattern completion mechanisms, partial sensory cues can trigger full experiential recall and associated physiological states.

Emotional Memory Reconsolidation: Multisensory cues enable safe reactivation of trauma memories for therapeutic reprocessing. The olfactory pathway provides direct limbic system access, bypassing cortical processing for gentler trauma work.

Interactive Biofeedback: Real-time physiological monitoring enables adaptive sensory modulation, closing the loop between intervention and response to optimize individual outcomes while preventing overwhelm.

Validated by Elite Institutions

Over a decade of development has yielded 60+ commercial deployments operating flawlessly across three sectors:

Healthcare: NHS (UK), ARQ Centrum '45 (Dutch national PTSD center), Charité Berlin

Corporate Wellness: Mars, Barclays, KLM Royal Dutch Airlines, Givaudan

Research: TNO, University of Amsterdam, CNRS/INSERM (France), INRS (Canada), Federal University of Porto Alegre

Independent, peer-reviewed studies from these institutions confirm large effect sizes that meet or exceed clinically significant thresholds. Our technology has been selected as the preferred platform for controlled immersive research by leading European neuroscience centers.

Dual-Track Commercial Model

We've structured a risk-mitigated go-to-market approach:

Track 1: Preventive Wellness (Immediate Revenue) — Corporate and institutional deployments addressing the global burnout epidemic affecting 82% of workers. Hardware-as-a-service leasing at €750–2,200 monthly provides rapid stress relief with measurable ROI.

Track 2: Clinical Applications (High-Margin Expansion) — Medical-grade configurations for PTSD, addiction recovery, anxiety disorders, and chronic pain management. Pricing at €1,500–2,500 monthly with evidence demonstrating 20–50% enhancement of existing therapeutic protocols.

Unit Economics: 68–72% gross margins, 8–18 month payback periods, 4–8x lifetime value to customer acquisition cost ratios, and 70% recurring revenue mix.

Exceptional Capital Efficiency

• Cash flow positive with €4M projected 2025 revenue and €700K EBITDA
• Zero major technical failures across 60+ units over eight years
• Only €2.15M invested to reach this stage (grants + seed equity)
• Built on the foundation of a profitable sister company with 20 years of operational history

The Goldilocks Investment Window

Market Dynamics

• €82B European digital mental health market growing at 22.5% annually
• Mental health funding surged 38% in 2024 to $2.7B despite economic headwinds
• European Series A rounds averaging €16M (up 42% year-over-year)
• AI-enabled healthtech commanding 6–8x revenue multiples versus 4–6x for standard digital health

Competitive Moat

• Proprietary affective data: Ten years of sensory-biometric-emotional state correlations impossible for competitors to replicate
• Patent protection: Granted patents on multisensory orchestration and bio-adaptive systems
• First-mover advantage: Only platform integrating six+ modalities with real-time AI personalization
• Network effects: Dataset value compounds as deployment scale increases

Sensiks enters at an attractive €27M pre-money valuation with proven technology, clinical validation, and revenue generation—offering superior risk-adjusted returns compared to earlier-stage competitors or inflated late-stage valuations.

36-Month Path to Scale

This €8M raise funds:

• V2 platform launch (mid-2026): Next-generation modular, sustainable design currently 80% complete
• Clinical validation: Three RCTs across PTSD, addiction, and workplace stress
• Commercial scaling: 75 to 350+ unit deployment trajectory
• SENSAI advancement: AI engine refinement for enhanced personalization
• Regulatory progress: MDR Class IIa and FDA pathway execution

Financial Targets (V2 Revenue Only)

• 2026: 75 units, €2.5M revenue
• 2027: 350 units, €8.5M revenue, breakeven
• 2028: 1,000 units, €18M revenue, positive EBITDA
• 2030: 3,265 units, €60M cumulative revenue

Exit Scenarios: Multiple Paths to Returns

Strategic Acquisition (Primary, 60% probability) — Target acquirers include Big Tech seeking health positioning (Philips, Google, Meta), MedTech leaders requiring digital capabilities (Siemens Healthineers), and digital health consolidators (Headspace Health). Anticipated 2030 valuation: €100–175M based on 8–15x ARR multiples with data asset premiums.

IPO (Secondary, 25% probability) — Euronext or NASDAQ listing in 2030–2031 at €300–800M market cap, requiring €50–100M revenue run rate and regulatory clearances.

Expected Investor Returns: 3–10x over 4–5 years through combination of commercial scaling, regulatory value inflection, and data moat expansion.

Why Now?

• De-risked technology with proven efficacy and blue-chip validation
• Product-market fit demonstrated through positive cash flow and institutional adoption
• Pre-regulatory approval valuation captures upside from upcoming MDR/FDA submissions
• Pre-consolidation positioning ahead of strategic interest and competitive crowding
• Favorable funding environment for AI-enabled healthtech with clinical validation

Team & Location

Led by founder with 20+ years in sensory wellness innovation and proven track record (25,000+ legacy installations). Core team of 9 FTEs with 5–7 year average tenure based in the Eindhoven innovation corridor, providing access to ASML, Philips, and NXP engineering talent.

Next Steps

• Comprehensive investor deck with detailed financials
• Customer reference calls and site visits
• Technical evaluation and product demonstrations
• Strategic partnership discussions

Contact

invest@sensiks.com | www.sensiks.com

Fred Galstaun, CEO/Founder

+31 650 252 069

Confidential & Proprietary | For Qualified Investors Only | November 2025

SENSIKS — Executive Summary (PDF)

Embedded viewer with controls. Best viewed fullscreen on desktop.

Open PDF in new tab · Download PDF

SENSIKS: PIONEERING SENSORY REALITY FOR MENTAL HEALTH & WELLBEING

Executive Summary – Updated October 2025

The Opportunity

The global mental health crisis—affecting 1B+ people with burnout, depression, anxiety, PTSD, addictions, and chronic stress—costs $1T+ annually (WHO), intensified by post-COVID challenges, geopolitical instability, and societal pressures. In the U.S., 1 in 5 adults experiences mental illness, with 55–70% untreated due to barriers including stigma, cost, and access (NIMH, 2025).

Current solutions fall short: Pharmaceuticals offer symptomatic relief but carry side effects and 30–50% relapse rates; CBT and talk therapy are slow and costly with limited limbic access; digital apps and audiovisual VR achieve modest effect sizes (d=0.5–0.7); wearables measure but don't intervene. These fragmented, cognitive-chemical approaches leave a 70% unmet need for rapid, accessible, side-effect-free emotional regulation tools (APA).

The Solution: Sensory Reality

Sensiks addresses this gap with Sensory Reality (SR), the world's first full-stack closed-loop platform for multisensory integration (MSI) since 2011. Developed with TNO/Delft University and government grants, SR transforms audiovisual VR, digital health, and CBT into full-spectrum experiences through bio-adaptive Pods.

Platform Architecture

Hardware: Bio-Adaptive Pods

• Visual: 1,800–6,500K CCT LED arrays for circadian spectrum control
• Audio: Immersive 7.1 spatial soundscapes with sub-50ms latency
• Olfactory: IFRA-aligned programmable scent cartridges
• Haptic: 20–120 Hz vibration with 40Hz gamma mode
• Thermal: Warm/cool gradient generation via IR heating
• Airflow: 0.0–0.8 m/s directional patterns
• Sensors: Continuous HRV, GSR, respiration, motion tracking, optional EEG

Software & AI: StateShifter Intelligence

• Real-time biofeedback fusion from multiple sources (HRV, GSR, EEG)
• Affective state modeling (arousal, valence, cognitive load)
• Sub-second latency from sensor to actuation
• Personalized response models (4x faster target-state by session 10)
• Content library with therapeutic protocols and SDK/API

Validated Science

Independent Research (2021-2025)

80-90% of peer-reviewed studies confirm MSI enhances therapeutic outcomes by 20–50% over single-modality interventions (Cohen's d ≈ 0.6–0.8). Key findings from investigator-initiated studies:

• Kindt & Soeter (2023, Frontiers in Psychiatry): Veterans PTSD study using Sensiks for multisensory memory reactivation + imagery rescripting + propranolol showed 4/7 participants with 30-40 point PCL-5 reductions; 5/7 showed QoL improvements
• de Jesus (2025, INRS-EMT): Ultra-Reality (multisensory) showed deeper relaxation vs standard AV-VR (p<.01); positive effects lasting 3 months in responders; EEG neuromarkers predict improvement by session 3
• Vermetten et al. (2021, Frontiers in VR): Personalized multisensory cues intensified emotional recall and engagement in veterans; proper congruency and monitoring maintains therapeutic window of tolerance
• Lopes & Falk (2024, Frontiers in VR): Systematic review showed positive impact from adding olfactory components; outcomes comparable to real nature exposure

Mechanisms Validated:

• Multisensory Integration: Engages insula, amygdala, hippocampus, prefrontal cortex for enhanced presence and emotional salience
• Autonomic Regulation: HRV improvements of 20-30%, indicating vagal activation and HPA-axis downregulation
• Psychoneuroimmunology: Cortisol reduction 15-40%, supporting immune balance
• Neuroplastic Pathways: Memory reconsolidation and adaptive emotional relearning

Applications

Preventive Wellbeing (€750/mo tier)

• 10-20 minute sessions for stress recovery and resilience
• Corporate wellness, healthcare settings, care homes
• Objective metrics (HRV, GSR) for program validation

Therapeutic Adjunct (€1,500-2,500/month tier)

• Enhances CBT, VRET, EMDR with embodied regulation
• Clinician-controlled protocols with real-time biofeedback
• GDPR/HIPAA compliant; pathway to MDR/FDA clearance

Research Platform (€1,200-2,000/month tier)

• Programmable APIs for custom protocols
• Multi-modal data capture (HRV, EEG, GSR, motion)
• Academic and commercial R&D applications

Proven Deployment

• 60+ MVP installations since 2017 (8+ years robust operation)
• Prestigious clients: NHS, UK Ministry of Defence, ARQ National Psychotrauma Centre, universities, KLM, Givaudan, Mars, Barclays, PwC, Tony Robbins
• 25,000+ legacy cabinets deployed since 2005
• Independent peer-reviewed research from LUMC, ARQ, TNO, INRS-EMT

V2 ROADMAP (Q1 2026 Launch)

• Scalable modular hardware architecture
• Expanded SDK with AI-generated content tools
• Enhanced real-time adaptive dosing algorithms
• Pathway to wellness device certification
• Optional medical device classification for therapeutic claims

Market Opportunity

Positioned at intersection of high-growth sectors:

• Corporate Wellness: $68.02B (2024) → $130.03B (2034)
• Behavioral Health: $184.94B (2024) → $330.35B (2034)
• VR/AR Healthcare: $1.9B (2024) → $2.4B (2025), +26% YoY (fastest growth)
• Mental Health Tech: $1.94B (2024) → $5.6B (2025), +16% YoY
• Digital Therapeutics: $3.2B (2024) → $3.8B (2025), +19% YoY

Total Addressable Market (TAM): $785B+

Serviceable Obtainable Market (SOM):

• Near-term: €200–500M
• By 2030: €1B+

Competitive Advantage

Investment trends favor Sensiks positioning:

• ✓ B2B enterprise model (vs. challenged D2C apps)
• ✓ Hardware + software moat (premium valuations)
• ✓ Clinical validation (peer-reviewed research)
• ✓ AI integration (37% of 2024 digital health funding)
• ✓ Multi-stream revenue (HaaS + SaaS + content licensing)

Differentiation: Only platform offering full 5+ sense integration with AI orchestration and biofeedback, vs. competitors limited to visual-audio VR (AppliedVR $71M, XRHealth $40M, Limbix $38.5M, Tripp $28.2M).

Business Model

Hybrid recurring revenue:

• Hardware-as-a-Service: 35–55% gross margins
• SaaS subscriptions: 85–90% gross margins
• Content marketplace: 70–85% gross margins

Tiered Pricing:

• Preventive Wellbeing: €750/mo
• Clinical/Therapeutic: €1,500–2,500/month
• Research Platform: €1,200–2,000/month

Financial Projections:

• 2029 Revenue: €82M
• Recurring Revenue: 45%
• Path to 350-850 deployed units within 3 years

Investment Opportunity

Seeking: €8M Series A at €35M post-money valuation (tranched)

Use of Funds:

• V2 production and scaling
• Randomized controlled trials (RCTs)
• Regulatory pathways (MDR/FDA)
• Market expansion (EU, US, Canada)
• Sales and clinical team expansion

Exit Potential:

3–5x returns through:

• Strategic acquisition (digital health platforms, pharma, wellness providers)
• IPO in high-growth AI-neurotech sector
• Recent comparables: BehaVR acquired by XRHealth, Limbix by Big Health

Market Timing: Optimal window before major consolidation; VR/AR healthcare growing fastest (26% YoY); hardware-enabled platforms commanding 4-8x ARR valuations.

The Paradigm Shift

Sensiks bridges cognitive and embodied health as a new category—"Sensory Reality"—enhancing resilience, quality of life, and emotional processing without side effects. By uniting multisensory neuroscience, affective AI, and bio-adaptive hardware, we deliver measurable pathways for stress regulation and therapeutic enhancement, creating scalable infrastructure for the future of embodied digital health.

From therapy rooms to everyday environments, Sensiks provides the missing link: a scientifically-validated, hardware-enabled platform that makes emotional regulation accessible, effective, and side-effect-free /